Leveraging gene expression subgroups to classify DLBCL patients and select for clinical benefit from a novel agent

Overview of attention for article published in Blood, January 2020

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (69th percentile)
Good Attention Score compared to outputs of the same age and source (67th percentile)

Mentioned by

twitter: 3 X users

patent: 1 patent

Readers on

mendeley: 50 Mendeley

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 57,819 followers.

Blood Commentary: Leveraging gene expression subgroups to classify DLBCL patients and select for clinical benefit from a novel agent https://t.co/ONgcRVh4pL

Leveraging Gene Expression Subgroups to Classify DLBCL Patients and Enrich for Clinical Benefit to a Novel Agent. #lymphoma #lymsm https://t.co/KGEFj9OnGx

New article: Leveraging Gene Expression Subgroups to Classify DLBCL Patients and Enrich for Clinical Benefit to a Novel Agent. https://t.co/tHq2CsSKsc #DLBCL #lymsm #hematology

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.